
This is an unofficial archive of PsychonautWiki as of 2025-08-11T15:14:44Z. Content on this page may be outdated, incomplete, or inaccurate. Please refer to the original page for the most up-to-date information.
Template:SubstanceBox/LSD: Difference between revisions
Jump to navigation
Jump to search
>Quack The current citation for the bioavailability for the Sublingual ROA is actually referencing the "... assuming [of] an oral bioavailability of 71%..." on page 5 and 6. Upon further research there exist a more concurrent article to contrast this figure, concluding a new bioavailability closer to 100% on page 1149. |
>Graham m wiki ref formatting |
||
Line 50: | Line 50: | ||
<!-- Dosage/Duration per ROA --> | <!-- Dosage/Duration per ROA --> | ||
|OralROA= | |OralROA=false | ||
|OralROA_Collapsed= | |OralROA_Collapsed=true | ||
|OralROA_Caption= | |OralROA_Caption= | ||
|OralROA_Bioavailability= | |OralROA_Bioavailability= | ||
|OralROA_Threshold= | |OralROA_Threshold= | ||
|OralROA_Light= | |OralROA_Light= | ||
Line 71: | Line 71: | ||
|SublingualROA_Collapsed=false | |SublingualROA_Collapsed=false | ||
|SublingualROA_Caption= | |SublingualROA_Caption= | ||
|SublingualROA_Bioavailability= | |SublingualROA_Bioavailability=[[Sublingual min bioavailability::71]]% - [[Sublingual max bioavailability::71]]%<ref>{{cite journal | vauthors=((Dolder, P. C.)), ((Schmid, Y.)), ((Haschke, M.)), ((Rentsch, K. M.)), ((Liechti, M. E.)) | journal=International Journal of Neuropsychopharmacology | title=Pharmacokinetics and Concentration-Effect Relationship of Oral LSD in Humans | volume=19 | issue=1 | pages=1–7 | date= January 2016 | url=https://academic.oup.com/ijnp/article-lookup/doi/10.1093/ijnp/pyv072 | issn=1461-1457 | doi=10.1093/ijnp/pyv072}}</ref> | ||
|SublingualROA_Microdose= | |SublingualROA_Microdose= | ||
|SublingualROA_Threshold=[[Sublingual threshold dose::15]] [[Sublingual dose units::µg]] | |SublingualROA_Threshold=[[Sublingual threshold dose::15]] [[Sublingual dose units::µg]] |
Revision as of 23:37, 29 June 2022
SubstanceBox/LSD | |||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Chemical Nomenclature | |||||||||||||||||||||||||||||||||||
Common names | LSD, LSD-25, Lucy, L, Acid, Cid, Tabs, Blotter | ||||||||||||||||||||||||||||||||||
Substitutive name | d-Lysergic acid diethylamide | ||||||||||||||||||||||||||||||||||
Systematic name | (6aR,9R)-N,N-Diethyl-7-methyl-4,6,6a,7,8,9-hexahydroindolo-[4,3-fg]quinoline-9-carboxamide | ||||||||||||||||||||||||||||||||||
Class Membership | |||||||||||||||||||||||||||||||||||
Psychoactive class | Psychedelic | ||||||||||||||||||||||||||||||||||
Chemical class | Lysergamide | ||||||||||||||||||||||||||||||||||
Routes of Administration | |||||||||||||||||||||||||||||||||||
|
- ↑ Dolder, P. C., Schmid, Y., Haschke, M., Rentsch, K. M., Liechti, M. E. (January 2016). "Pharmacokinetics and Concentration-Effect Relationship of Oral LSD in Humans". International Journal of Neuropsychopharmacology. 19 (1): 1–7. doi:10.1093/ijnp/pyv072. ISSN 1461-1457.